Is it time to bail out of easyJet plc and buy GlaxoSmithKline plc instead?

A warning shot from easyJet plc (LON: EZJ) diverts attention to stable enterprises such as GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The main takeaway I get from today’s half-year report from airline operator easyJet (LSE: EZJ) is that net cash from operations is down 40% compared to the equivalent period last year and the firm made an earnings-per-share loss of 5.1p, which compares to a profit of 1.3p per share last year.

No wonder, then, at 1,500p, the shares are down around 14% since the beginning of 2016. Whichever way we dress it up, this isn’t a good result for easyJet and the firm’s shareholders.

Precarious profits

The outcome here demonstrates what a precarious juggling act it is to keep an airline profitable and growing. During the period, easyJet faced pressure on its business from justifiably skittish customers due to travel strikes and terror attacks on European capitals.

That’s the thing with an airline: we never know when a natural disaster such as an Icelandic volcano or man-made disasters such as war, conflict, strike, terrorism or commodity speculation will shoot down the firm’s profitability. But it gets worse than that. Airlines are also at the mercy of macroeconomic events making airline businesses and their shares among the most cyclical on the stock market.

That cyclicality has implications about how the market is likely to value businesses such as easyJet. The more mature a macro-cycle becomes, the lower I would expect easyJet’s valuation to be as the market tries to anticipate the next cyclical down-leg by discounting high earnings in the boom times.

Consumer demand strong

Right now, easyJet trades on a forward price-to-earnings (P/E) ratio of nine for the year to September 2017 and sports a twice-covered 4.7% dividend yield. I wouldn’t expect a higher valuation than that, so any further share price progress probably needs to come from business growth rather than from a valuation rerating.

Carolyn McCall, easyJet’s chief executive says: easyJet has delivered a robust financial performance during the half year despite the well-publicised external events. Underlying consumer demand has been strong with UK beach traffic providing a healthy start to the half and easyJet’s biggest-ever ski season helping to deliver increased passenger numbers and higher revenue during H1.

Okay. But it’s precisely when things are going at their best that we should expect a cyclical top, often followed by a descent into the next cyclical bottom. Nobody knows when the top will arrive, but I’m taking these first-half losses as a warning shot and now I’m avoiding easyJet shares.

A more robust business model

Pharmaceutical giant GlaxoSmithKline (LSE: GSK) enjoys a more robust business model than easyJet’s. The stable nature of demand for medicines makes GlaxoSmithKline’s operation far less cyclical and keeps the cash taps flowing as consumers repeat purchase drugs.

Sure, the pharmaceutical industry had its challenges over patent expiry issues as once high-earning formulations lost exclusivity in the market and the firm saw a flood of generic competition erode profits. However, the company is moving on from that and hopes a new generation of blockbusters will return the firm to enduring growth.

City analysts following the firm expect earnings to grow 16% this year and 4% during 2014. At today’s 1,475p share price GlaxoSmithKline trades on a forward P/E rating of just over 16 for 2017 and yields a dividend of 5.4% covered just over once by forward earnings. That’s a fair valuation for a defensive business with reasonable forward growth prospects.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

1 top FTSE 100 growth stock to consider buying before the end of May

Consistent growth from this FTSE 100 performer looks set to continue, so I’d consider the shares now for a diversified…

Read more »

Investing Articles

Here’s where I see the Legal & General share price ending 2024

After a choppy start to the year, Charlie Carman explores where the Legal & General share price could go over…

Read more »

Investing Articles

3 steps to earning £100 a month in passive income

Earning passive income from stocks is simple but not easy. Stephen Wright outlines the way to aim for £100 per…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

Where will the Rolls-Royce share price end 2024, above 500p or below 400p?

Will the Rolls-Royce share price ride higher in 2024, or will we see a fall back to lower valuations? Either…

Read more »

Black father and two young daughters dancing at home
Investing Articles

Turning a £20k ISA into a £33,000 passive income machine

A Stocks and Shares ISA can be turned into a powerful vehicle capable of throwing off attractive passive income streams…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

The Lloyds share price just hit a 52-week high. Can it fly still higher?

The Lloyds Bank share price has followed NatWest upwards this year. Shareholder patience just might be paying off.

Read more »

Investing Articles

£8,000 in cash? Here’s how I’d invest for a £6,960 second income

Investing for a second income isn't always about investing in dividend-paying stocks. Dr James Fox details his growth-oriented strategy.

Read more »

Hand of a mature man opening a safety deposit box.
Investing Articles

10.8% dividend yield! 2 cheap stocks to consider for a £2,060 passive income

Many of us invest for a passive income, and these two stocks could be among the best out there for…

Read more »